AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03784625
Drug: [131I]ICF01012 (therapeutic dose level 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 800 MBq/m²
Trial: NCT03784625
Drug: [131I]ICF01012 (therapeutic dose level 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 1600 MBq/m²
Trial: NCT01387282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
Trial: NCT03784625
Drug: [131I]ICF01012 (therapeutic dose level 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 2700 MBq/m²
Trial: NCT03784625
Drug: [131I]ICF01012 (therapeutic dose level 4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 4000 MBq/m²
Trial: NCT01368003
Drug: STA9090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
Trial: NCT03086278
Drug: AST-008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-008 is a toll-like receptor 9 agonist.
Trial: NCT03265470
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
Trial: NCT01321060
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
Trial: NCT02744703
Drug: total-etch adhesive
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator use of total-etch adhesive
Trial: NCT02744703
Drug: self-etch adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator use of total-etch adhesive
Trial: NCT00788073
Drug: STX209
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
Trial: NCT00788073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
Trial: NCT02661126
Drug: MK-3682B
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
Trial: NCT03755167
Drug: IPL344
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
Trial: NCT02611518
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
Trial: NCT01921426
Drug: GC4419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
Trial: NCT00353158
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
Trial: NCT01923987
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~* Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~* Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~* 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~* Bevacizumab 5 mg/kg IV over 90 mins on Day 1~* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~* FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~* Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)
Trial: NCT03890185
Drug: Chemo alone
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
Trial: NCT01268020
Drug: [18F]-FMH3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
Trial: NCT03588156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02127593
Drug: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
Trial: NCT02127593
Drug: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
Trial: NCT01869881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100mg 2 tablets, bid, 400mg/day
Trial: NCT01667692
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.\[1\] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
Trial: NCT01667692
Drug: clarithmycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
Trial: NCT02925832
Drug: Proparacaine
RxNorm normalized name: proparacaine
DrugBank: Proparacaine (DB00807)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For anaesthetising conjunctiva
Trial: NCT03841448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
Trial: NCT01303783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
Trial: NCT01020383
Drug: ReoPro®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
Trial: NCT03792919
Drug: Stop current treatment (anti-HBV neucleos(t)ides)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
Trial: NCT01517100
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabinoid Receptor 1 antagonist
Trial: NCT00901628
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg intraoperative periarticular injection
Trial: NCT01403311
Drug: 5-Aminolevuline Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
Trial: NCT00901628
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 microgram (1:1000) intraoperative periarticular injection
Trial: NCT04478266
Drug: Amcenestrant-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablets Route of Administration: Oral
Trial: NCT04478266
Drug: SAR439859
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablets Route of Administration: Oral
Trial: NCT00391729
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
Trial: NCT00391729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take placebo QD, BID for 4-6 weeks
Trial: NCT01021995
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drops, 0.9 ml tid for 4 months
Trial: NCT02465645
Drug: Carvedilol + Simvastatin
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01613534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon plasma coagulation treatment followed by placebo administration for four weeks
Trial: NCT04594343
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
Trial: NCT04594343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
Trial: NCT02389985
Drug: CRLX101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01501799
Drug: Placebo (Vehicle Gel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel
Trial: NCT04447040
Drug: Acetaminophen/naproxen sodium Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
Trial: NCT04447040
Drug: Acetaminophen/naproxen sodium Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
Trial: NCT04447040
Drug: Acetaminophen/naproxen sodium Dose C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
Trial: NCT04447040
Drug: Acetaminophen/naproxen sodium Dose D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
Trial: NCT04447040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered as a single two-tablet dose.
Trial: NCT02506790
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00257608
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT00292396
Drug: Anti IL-12 monoclonal antibody/ABT-874
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please see Arm Description for intervention description and details.
Trial: NCT00292396
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 doses
Trial: NCT02516241
Drug: MEDI4736 (Durvalumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT03907280
Drug: BI 1265162 (R)
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concentrate for i.v. solution
Trial: NCT01854658
Drug: GP MDI (PT001)
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI administered as two puffs BID
Trial: NCT01854658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00685542
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02597868
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
Trial: NCT00704418
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT00704418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT02537028
Drug: MSC2364447C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
Trial: NCT02537028
Drug: MSC2364447C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
Trial: NCT02537028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
Trial: NCT04618913
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Molecular Weight Heparin
Trial: NCT03835871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug: placebo
Trial: NCT03835871
Drug: 400 µg per day Beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug: Beclomethasone 400 µg HFA per day
Trial: NCT03835871
Drug: 200 µg per day Beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug: Beclomethasone 200 µg HFA per day
Trial: NCT03835871
Drug: 100 µg per day Beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug: Beclomethasone 100 µg HFA per day
Trial: NCT06187584
Drug: Hydrocodone/acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/acetaminophen 0.15mg/kg PO q6
Trial: NCT06187584
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg PO q6 hours
Trial: NCT06187584
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/kg PO q6 hours
Trial: NCT03825757
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT01216111
Drug: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
Trial: NCT02174939
Drug: Dummy Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet twice per day for 12 weeks
Trial: NCT03110926
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Chemotherapy
Trial: NCT01182610
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5FU 225mg/m2/day on Days 1-15 and 22-36
Trial: NCT00338247
Drug: lapatinib + capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT03138603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
Trial: NCT02010242
Drug: GKT137831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
Trial: NCT02010242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
Trial: NCT01190683
Drug: cholecalciferol and calcium carbonate
RxNorm normalized name: calcium carbonate / cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
Trial: NCT02638831
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
Trial: NCT04418674
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.
Trial: NCT02495831
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 50 mg single dose
Trial: NCT02495831
Drug: Diclofenac sodium and safinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg single dose and safinamide 200 mg single dose
Trial: NCT01565720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03950570
Drug: ORIN1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORIN1001 will be administered as a table as a monotherapy in the dose escalation phase in patients with advanced solid tumors or in combination with Abraxane in patients with relapse, refractory breast cancer
Trial: NCT01464827
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-450 tablets
Trial: NCT01464827
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-333 tablets
Trial: NCT01464827
Drug: ABT-267
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-267 tablets
Trial: NCT03463044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00544765
Drug: TAC
RxNorm normalized name: TAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
Trial: NCT00810732
Drug: Open
RxNorm normalized name: Pyopen
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
Trial: NCT00810732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for sitaxsentan, orally administered once daily (double blind arm)
Trial: NCT03618550
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Trial: NCT01095003
Drug: Vinflunine plus Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Trial: NCT01095003
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks